Biotechnology • Pharmaceuticals • Disruptive Innovation
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than thirty companies, including twelve which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Sapphire Energy; Ikaria; Kythera Biopharmaceuticals (KYTH), Aviron (AVIR, acquired by Medimmune-MEDI); Agios Pharmaceuticals (AGIO), NetBot (acquired by Excite-ATHM); R2 Technology (acquired by Hologic-HOLX); XenoPort (XNPT); Caliper Life Sciences (CALP, acquired by PerkinElmer); Trubion Pharmaceuticals (TRBN, acquired by Emergent BioSolutions-EBS), Adolor (ADLR, acquired by Cubist-CBST); Array BioPharma (ARRY); deCODE Genetics (acquired by Amgen-AMGN); Nanosys; GenVec (GNVC); IDUN Pharmaceuticals (acquired by Pfizer-PFE); Genomica (GNOM, acquired by Exelixis-EXEL); Classmates.com (acquired by United Online-UNTD); Nura (acquired by Omeros-OMER); Receptos (RCPT); Kilimanjaro Energy; Bluebird Bio (BLUE); Hua Medicine; VLST; Ensemble Therapeutics; Accelerator; Theraclone Sciences; Fate Therapeutics (FATE); Juno Therapeutics, Sage Therapeutics, and Everyday Learning Corporation (acquired by Tribune Corp.-TRIB.)
Mr. Nelsen is a director of Agios Pharmaceuticals, Ikaria, Juno Therapeutics, Kythera Biopharmaceuticals, Sapphire Energy, Fate Therapeutics, Sage Therapeutics, Ensemble Therapeutics, and serves as Chairman of Hua Medicine. He also serves as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and is a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.